In fact, a recent study demonstrated that pre-therapeutic plasma interleukin (IL)-6 levels were correlated with the expression of nuclear factor (NF)-κB in the nuclei of tumor cells as well as the expression of IL-6 in local tumor sites, and that the plasma IL-6 level is an independent negative prognostic factor for overall survival (OS) of patients with castration-resistant prostatic carcinoma [10]. This evidence concerns the gene IL6 and neoplasm.